Growth factor delivery-based tissue engineering: General approaches and a review of recent developments

Journal of the Royal Society Interface

Volumn 8, Issue 55, 2011, Pages 153-170

  Lee, Kangwon ^a,b   Silva, Eduardo A ^b   Mooney, David J ^a,b  

^a HARVARD UNIVERSITY   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

Biomaterials; Nanoparticles; Regenerative medicine; Stimuli responsive materials; Synthetic extracellular matrix

Indexed keywords

BIOACTIVITY; BIOMATERIALS; NANOPARTICLES; PEPTIDES; TISSUE; TISSUE ENGINEERING;

CLINICAL TRIAL; COMMON DENOMINATORS; DESIGN STRATEGIES; GENERAL APPROACH; GROWTH FACTOR; GROWTH FACTOR DELIVERY; MATERIALS SCIENCE AND ENGINEERING; MATERIALS SYSTEMS; MORPHOGENS; RECENT PROGRESS; REGENERATIVE MEDICINE; SPATIO-TEMPORAL; STIMULI-RESPONSIVE MATERIALS; SYNTHETIC EXTRACELLULAR MATRIX; THERAPEUTIC AGENTS; THERAPEUTIC EFFECTS; TISSUE REGENERATION;

GROWTH (MATERIALS);

BIOMATERIAL; BIOPOLYMER; BONE MORPHOGENETIC PROTEIN 2; DEXTRIN; FIBROBLAST GROWTH FACTOR 2; GROWTH FACTOR; MATRIX METALLOPROTEINASE; NANOPARTICLE; NERVE GROWTH FACTOR; OLIGOPEPTIDE; OSTEOGENIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR AB; POLY(ORTHO ESTER); POLYANHYDRIDE; POLYGLUTAMIC ACID; POLYLACTIDE; RECEPTOR FOR ACTIVATED C KINASE 1; SCATTER FACTOR; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANGIOGENESIS; BONE DEFECT; CARDIOVASCULAR DISEASE; CHEMICAL BOND; DRUG DELIVERY SYSTEM; DRUG RELEASE; ENCAPSULATION; EXTRACELLULAR MATRIX; FLUORESCENCE RESONANCE ENERGY TRANSFER; FRACTURE; FREEZE DRYING; HUMAN; HYDROGEL; LEACHING; LIPOSOMAL DELIVERY; PH; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE SEPARATION; PROTEIN INTERACTION; REGENERATIVE MEDICINE; REVIEW; SIGNAL TRANSDUCTION; SYNTHETIC BIOLOGY; TEMPERATURE; TISSUE ENGINEERING;

EID: 78650842405     PISSN: 17425689     EISSN: 17425662     Source Type: Journal    
DOI: 10.1098/rsif.2010.0223     Document Type: Review

References (195)

1. Lanza, R. P., Langer, R. S. & Vacanti, J. 2007 Principles of tissue engineering. Amsterdam, The Netherlands: Elsevier Academic Press.
2. Cross, M. & Dexter, T. M. 1991 Growth factors in development, transformation, and tumorigenesis. Cell 64, 271-280. (doi:10.1016/0092-8674(91) 90638-F) (Pubitemid 121001254)
3. Cao, L., Arany, P. R., Wang, Y. S. & Mooney, D. J. 2009 Promoting angiogenesis via manipulation of VEGF responsiveness with notch signaling. Biomaterials 30, 4085-4093. (doi:10.1016/j.biomaterials.2009.04.051)
4. Discher, D. E., Janmey, P. & Wang, Y. L. 2005 Tissue cells feel and respond to the stiffness of their substrate. Science 310, 1139-1143. (doi:10.1126/science.1116995)
5. Ramirez, F. & Rifkin, D. B. 2003 Cell signaling events: a view from the matrix. Matrix Biol. 22, 101-107. (doi:10.1016/S0945-053X(03)00002-7)
6. Cohen, G. B., Ren, R. & Baltimore, D. 1995 Modular binding domains in signal transduction proteins. Cell 80, 237-248. (doi:10.1016/0092-8674(95) 90406-9)
7. Lamalice, L., Le Boeuf, F. & Huot, J. 2007 Endothelial cell migration during angiogenesis. Circ. Res. 100, 782-794. (doi:10.1161/01.RES.0000259593. 07661.1e)
8. Cao, L. & Mooney, D. J. 2007 Spatiotemporal control over growth factor signaling for therapeutic neovascularization. Adv. Drug Deliv. Rev. 59, 1340-1350. (doi:10. 1016/j.addr.2007.08.012)
9. Guo, W. & Giancotti, F. G. 2004 Integrin signalling during tumour progression. Nat. Rev. Mol. Cell Biol. 5, 816-826. (doi:10.1038/nrm1490)
10. Tucker, G. C. 2006 Integrins: molecular targets in cancer therapy. Curr. Oncol. Rep. 8, 96-103. (doi:10.1007/s11912-006-0043-3)
11. Kim, J. H., Kushiro, K., Graham, N. A. & Asthagiri, A. R. 2009 Tunable interplay between epidermal growth factor and cell-cell contact governs the spatial dynamics of epithelial growth. Proc. Natl. Acad. Sci. USA 106, 11 149-11 153. (doi:10.1073/pnas.0812651106)
12. Yanagisawa-Miwa, A. et al. 1992 Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 257, 1401-1403. (doi:10.1126/science.1382313)
13. Bauters, C., Asahara, T., Zheng, L. P., Takeshita, S., Bunting, S., Ferrara, N., Symes, J. F. & Isner, J. M. 1994 Physiological assessment of augmented vascularity induced by VEGF in ischemic rabbit hindlimb. Am. J. Physiol. 267, H1263-H1271.
14. Freedman, S. B. & Isner, J. M. 2002 Therapeutic angiogenesis for coronary artery disease. Ann. Intern. Med. 136, 54-71.
15. Takeshita, S., Pu, L. Q., Stein, L. A., Sniderman, A. D., Bunting, S., Ferrara, N., Isner, J. M. & Symes, J. F. 1994 Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. Circulation 90, II228-II234.
16. Takeshita, S., Zheng, L. P., Brogi, E., Kearney, M., Pu, L. Q., Bunting, S., Ferrara, N., Symes, J. F. & Isner, J. M. 1994 Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J. Clin. Invest. 93, 662-670. (doi:10.1172/JCI117018)
17. Rosengart, T. K., Lee, L. Y., Patel, S. R., Kligfield, P. D., Okin, P. M., Hackett, N. R., Isom, O.W. & Crystal, R. G. 1999 Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann. Surg. 230, 466-470. (Discussion 470-472.) (doi:10.1097/00000658-199910000-00002)
18. Schumacher, B., Pecher, P., Von Specht, B. U. & Stegmann, T. 1998 Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 97, 645-650.
19. Simons, M. et al. 2002 Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 105, 788-793. (doi:10.1161/hc0802.104407) (Pubitemid 34174916)
20. Krishnamurthy, R. & Manning, M. C. 2002 The stability factor: importance in formulation development. Curr. Pharm. Biotechnol. 3, 361-371. (doi:10.2174/1389201023378229)
21. Manning, M. C., Patel, K. & Borchardt, R. T. 1989 Stability of protein pharmaceuticals. Pharm. Res. 6, 903-918. (doi:10.1023/A:1015929109894)
22. Eppler, S. M., Combs, D. L., Henry, T. D., Lopez, J. J., Ellis, S. G., Yi, J. H., Annex, B. H., Mccluskey, E. R. & Zioncheck, T. F. 2002 A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin. Pharmacol. Ther. 72, 20-32. (doi:10. 1067/mcp.2002.126179)
23. Henry, T. D. et al. 2003 The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 107, 1359-1365. (doi:10.1161/01.CIR.0000061911.47710.8A)
24. Simons, M. & Ware, J. A. 2003 Therapeutic angiogenesis in cardiovascular disease. Nat. Rev. Drug Discov. 2, 863-871. (doi:10.1038/nrd1226)
25. Fischbach, C. & Mooney, D. J. 2007 Polymers for proand anti-angiogenic therapy. Biomaterials 28, 2069-2076. (doi:10.1016/j. biomaterials.2006.12.029)
26. Mitragotri, S. & Lahann, J. 2009 Physical approaches to biomaterial design. Nat. Mater. 8, 15-23. (doi:10.1038/nmat2344)
27. Richardson, T. P., Peters, M. C., Ennett, A. B. & Mooney, D. J. 2001 Polymeric system for dual growth factor delivery. Nat. Biotechnol. 19, 1029-1034. (doi:10.1038/nbt1101-1029)
28. Boontheekul, T., Hill, E. E., Kong, H. J. & Mooney, D. J. 2007 Regulating myoblast phenotype through controlled gel stiffness and degradation. Tissue Eng. 13, 1431-1442. (doi:10.1089/ten.2006.0356)
29. Datta, N., Pham, Q. P., Sharma, U., Sikavitsas, V. I., Jansen, J. A. & Mikos, A. G. 2006 In vitro generated extracellular matrix and fluid shear stress synergistically enhance 3D osteoblastic differentiation. Proc. Natl Acad. Sci. USA 103, 2488-2493. (doi:10.1073/pnas.0505661103)
30. Geng, Y., Dalhaimer, P., Cai, S., Tsai, R., Tewari, M., Minko, T. & Discher, D. E. 2007 Shape effects of filaments versus spherical particles in flow and drug delivery. Nat. Nanotechnol. 2, 249-255. (doi:10.1038/nnano.2007. 70)
31. Lutolf, M. P., Lauer-Fields, J. L., Schmoekel, H. G., Metters, A. T., Weber, F. E., Fields, G. B. & Hubbell, J. A. 2003 Synthetic matrix metalloproteinase-sensitive hydrogels for the conduction of tissue regeneration: engineering cell-invasion characteristics. Proc. Natl Acad. Sci. USA 100, 5413-5418. (doi:10.1073/pnas.0737381100)
32. Raeber, G. P., Lutolf, M. P. & Hubbell, J. A. 2005 Molecularly engineered PEG hydrogels: a novel model system for proteolytically mediated cell migration. Biophys. J. 89, 1374-1388. (doi:10.1529/biophysj.104.050682)
33. Rizzi, S. C., Ehrbar, M., Halstenberg, S., Raeber, G. P., Schmoekel, H. G., Hagenmuller, H., Muller, R., Weber, F. E. & Hubbell, J. A. 2006 Recombinant protein-co-PEG networks as cell-adhesive and proteolytically degradable hydrogel matrixes. Part II. Biofunctional characteristics. Biomacromolecules 7, 3019-3029. (doi:10.1021/bm060504a)
34. Carmeliet, P. 2003 Angiogenesis in health and disease. Nat. Med. 9, 653-660. (doi:10.1038/nm0603-653)
35. Carmeliet, P. 2005 Angiogenesis in life, disease and medicine. Nature 438, 932-936. (doi:10.1038/nature04478)
36. Risau, W. 1997 Mechanisms of angiogenesis. Nature 386, 671-674. (doi:10.1038/386671a0)
37. Chapanian, R. & Amsden, B. G. 2010 Combined and sequential delivery of bioactive VEGF(165) and HGF from poly(trimethylene carbonate) based photo-cross-linked elastomers. J. Control. Release 143, 53-63. (doi:10.1016/j.jconrel.2009.11.025)
38. Chen, R. R., Silva, E. A., Yuen, W. W., Brock, A. A., Fischbach, C., Lin, A. S., Guldberg, R. E. & Mooney, D. J. 2007 Integrated approach to designing growth factor delivery systems. FASEB J. 21, 3896-3903. (doi:10.1096/fj.06-7873com)
39. Marui, A. et al. 2005 Simultaneous application of basic fibroblast growth factor and hepatocyte growth factor to enhance the blood vessels formation. J. Vasc. Surg. 41, 82-90. (doi:10.1016/j.jvs.2004.10.029)
40. Simmons, C. A., Alsberg, E., Hsiong, S., Kim, W. J. & Mooney, D. J. 2004 Dual growth factor delivery and controlled scaffold degradation enhance in vivo bone formation by transplanted bone marrow stromal cells. Bone 35, 562-569. (doi:10.1016/j.bone.2004.02.027)
41. Basmanav, F. B., Kose, G. T. & Hasirci, V. 2008 Sequential growth factor delivery from complexed microspheres for bone tissue engineering. Biomaterials 29, 4195-4204.
42. Yilgor, P., Hasirci, N. & Hasirci, V. 2010 Sequential BMP-2/BMP-7 delivery from polyester nanocapsules. J. Biomed. Mater. Res. A 93, 528-536.
43. Yilgor, P., Tuzlakoglu, K., Reis, R. L., Hasirci, N. & Hasirci, V. 2009 Incorporation of a sequential BMP-2/BMP-7 delivery system into chitosan-based scaffolds for bone tissue engineering. Biomaterials 30, 3551-3559. (doi:10.1016/j.biomaterials.2009.03.024)
44. Patel, Z. S., Young, S., Tabata, Y., Jansen, J. A., Wong, M. E. & Mikos, A. G. 2008 Dual delivery of an angiogenic and an osteogenic growth factor for bone regeneration in a critical size defect model. Bone 43, 931-940. (doi:10.1016/j.bone.2008.06.019)
45. Raiche, A. T. & Puleo, D. A. 2004 In vitro effects of combined and sequential delivery of two bone growth factors. Biomaterials 25, 677-685. (doi:10.1016/S0142-9612(03)00564-7)
46. Freeman, I. & Cohen, S. 2009 The influence of the sequential delivery of angiogenic factors from affinity-binding alginate scaffolds on vascularization. Biomaterials 30, 2122-2131. (doi:10.1016/j.biomaterials.2008. 12.057)
47. Freeman, I., Kedem, A. & Cohen, S. 2008 The effect of sulfation of alginate hydrogels on the specific binding and controlled release of heparin-binding proteins. Biomaterials 29, 3260-3268. (doi:10.1016/j. biomaterials.2008.04.025)
48. Ehrbar, M. et al. 2004 Cell-demanded liberation of VEGF121 from fibrin implants induces local and controlled blood vessel growth. Circ. Res. 94, 1124-1132. (doi:10.1161/01.RES.0000126411.29641.08)
49. Ehrbar, M., Rizzi, S. C., Hlushchuk, R., Djonov, V., Zisch, A. H., Hubbell, J. A., Weber, F. E. & Lutolf, M. P. 2007 Enzymatic formation of modular cell-instructive fibrin analogs for tissue engineering. Biomaterials 28, 3856-3866. (doi:10.1016/j.biomaterials.2007.03.027)
50. Zisch, A. H., Schenk, U., Schense, J. C., Sakiyama-Elbert, S. E. & Hubbell, J. A. 2001 Covalently conjugated VEGF-fibrin matrices for endothelialization. J. Control. Release 72, 101-113. (doi:10.1016/S0168-3659(01) 00266-8)
51. Dawson, E., Mapili, G., Erickson, K., Taqvi, S. & Roy, K. 2008 Biomaterials for stem cell differentiation. Adv. Drug Deliv. Rev. 60, 215-228. (doi:10.1016/j.addr.2007.08.037)
52. Lutolf, M. P. & Hubbell, J. A. 2005 Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat. Biotechnol. 23, 47-55. (doi:10.1038/nbt1055)
53. Cross, M. J., Dixelius, J., Matsumoto, T. & Claesson-Welsh, L. 2003 VEGF-receptor signal transduction. Trends Biochem. Sci. 28, 488-494. (doi:10.1016/S0968-0004(03)00193-2)
54. Hood, J. D.,Frausto, R., Kiosses, W.B., Schwartz,M. A. & Cheresh, D. A. 2003 Differential alphav integrin-mediated Ras-ERK signaling during two pathways of angiogenesis. J. Cell Biol. 162, 933-943. (doi:10.1083/jcb. 200304105)
55. Hutchings, H., Ortega, N. & Plouet, J. 2003 Extracellular matrix-bound vascular endothelial growth factor promotes endothelial cell adhesion, migration, and survival through integrin ligation. FASEB J. 17, 1520-1522.
56. Tsou, R. & Isik, F. F. 2001 Integrin activation is required for VEGF and FGF receptor protein presence on human microvascular endothelial cells. Mol. Cell. Biochem. 224, 81-89. (doi:10.1023/A:1011947301849)
57. Hall, H. & Hubbell, J. A. 2004 Matrix-bound sixth Ig-like domain of cell adhesion molecule L1 acts as an angiogenic factor by ligating alphavbeta3-integrin and activating VEGF-R2. Microvasc. Res. 68, 169-178. (doi:10.1016/j.mvr.2004.07.001)
58. Li, B., Davidson, J. M. & Guelcher, S. A. 2009 The effect of the local delivery of platelet-derived growth factor from reactive two-component polyurethane scaffolds on the healing in rat skin excisional wounds. Biomaterials 30, 3486-3494. (doi:10.1016/j.biomaterials.2009.03.008)
59. Liu, X., Won, Y. & Ma, P. X. 2005 Surface modification of interconnected porous scaffolds. J. Biomed. Mater. Res. A 74, 84-91. (doi:10.1002/jbm.a.30367)
60. Park, H., Temenoff, J. S., Holland, T. A., Tabata, Y. & Mikos, A. G. 2005 Delivery of TGF-beta1 and chondrocytes via injectable, biodegradable hydrogels for cartilage tissue engineering applications. Biomaterials 26, 7095-7103. (doi:10.1016/j.biomaterials.2005.05.083)
61. Ikeuchi, M., Dohi, Y., Horiuchi, K., Ohgushi, H., Noshi, T., Yoshikawa, T., Yamamoto, K. & Sugimura, M. 2002 Recombinant human bone morphogenetic protein-2 promotes osteogenesis within atelopeptide type I collagen solution by combination with rat cultured marrow cells. J. Biomed. Mater. Res. 60, 61-69. (doi:10.1002/jbm.1281)
62. Silva, A. K., Richard, C., Bessodes, M., Scherman, D. & Merten, O.W. 2009 Growth factor delivery approaches in hydrogels. Biomacromolecules 10, 9-18. (doi:10.1021/bm801103c)
63. Schense, J. C. & Hubbell, J. A. 1999 Cross-linking exogenous bifunctional peptides into fibrin gels with factor XIIIa. Bioconjug. Chem. 10, 75-81. (doi:10.1021/bc9800769)
64. Sakiyama-Elbert, S. E., Panitch, A. & Hubbell, J. A. 2001 Development of growth factor fusion proteins for cell-triggered drug delivery. FASEB J. 15, 1300-1302.
65. Schmoekel, H. G., Weber, F. E., Schense, J. C., Gratz, K. W., Schawalder, P. & Hubbell, J. A. 2005 Bone repair with a form of BMP-2 engineered for incorporation into fibrin cell ingrowth matrices. Biotechnol. Bioeng. 89, 253-262. (doi:10.1002/bit.20168)
66. Ehrbar, M., Metters, A., Zammaretti, P., Hubbell, J. A. & Zisch, A. H. 2005 Endothelial cell proliferation and progenitor maturation by fibrin-bound VEGF variants with differential susceptibilities to local cellular activity. J. Control. Release 101, 93-109. (doi:10.1016/j.jconrel.2004.07.018) (Pubitemid 39600975)
67. Walpoth, B. H. et al. 2007 Enhanced intimal thickening of expanded polytetrafluoroethylene grafts coated with fibrin or fibrin-releasing vascular endothelial growth factor in the pig carotid artery interposition model. J. Thorac. Cardiovasc. Surg. 133, 1163-1170. (doi:10.1016/j.jtcvs.2007.01.029)
68. Sakiyama-Elbert, S. E. & Hubbell, J. A. 2000 Development of fibrin derivatives for controlled release of heparin-binding growth factors. J. Control. Release 65, 389-402. (doi:10.1016/S0168-3659(99)00221-7)
69. Nillesen, S. T., Geutjes, P. J., Wismans, R., Schalkwijk, J., Daamen, W. F. & Van Kuppevelt, T. H. 2007 Increased angiogenesis and blood vessel maturation in acellular collagen-heparin scaffolds containing both FGF2 and VEGF. Biomaterials 28, 1123-1131. (doi:10.1016/j.biomaterials.2006.10.029)
70. Ruppert, R., Hoffmann, E. & Sebald, W. 1996 Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. Eur. J. Biochem. 237, 295-302. (doi:10.1111/j.1432-1033.1996.0295n.x)
71. Sakiyama-Elbert, S. E. & Hubbell, J. A. 2000 Controlled release of nerve growth factor from a heparin-containing fibrin-based cell ingrowth matrix. J. Control. Release 69, 149-158. (doi:10.1016/S0168-3659(00)00296-0)
72. Scheufler, C., Sebald, W. & Hulsmeyer, M. 1999 Crystal structure of human bone morphogenetic protein-2 at 2.7 A resolution. J. Mol. Biol. 287, 103-115. (doi:10.1006/jmbi.1999.2590)
73. Sieron, A. L., Louneva, N. & Fertala, A. 2002 Site-specific interaction of bone morphogenetic protein 2 with procollagen II. Cytokine 18, 214-221. (doi:10.1006/cyto.2002.1035)
74. Wissink, M. J., Beernink, R., Pieper, J. S., Poot, A. A., Engbers, G. H., Beugeling, T., Van Aken, W. G. & Feijen, J. 2001 Binding and release of basic fibroblast growth factor from heparinized collagen matrices. Biomaterials 22, 2291-2299. (doi:10.1016/S0142-9612(00)00418-X)
75. Yoon, J. J., Chung, H. J. & Park, T. G. 2007 Photo-crosslinkable and biodegradable Pluronic/heparin hydrogels for local and sustained delivery of angiogenic growth factor. J. Biomed. Mater. Res. A 83, 597-605. (doi:10.1002/jbm.a.31271)
76. Lin, C. C. & Anseth, K. S. 2009 Controlling affinity binding with peptide-functionalized poly(ethylene glycol) hydrogels. Adv. Funct. Mater. 19, 2325. (doi:10.1002/adfm.200900107)
77. Lin, C. C., Boyer, P. D., Aimetti, A. A. & Anseth, K. S. 2010 Regulating MCP-1 diffusion in affinity hydrogels for enhancing immuno-isolation. J. Control. Release 142, 384-391. (doi:10.1016/j.jconrel.2009.11.022)
78. Maynard, H. D. & Hubbell, J. A. 2005 Discovery of a sulfated tetrapeptide that binds to vascular endothelial growth factor. Acta Biomater. 1, 451-459. (doi:10.1016/j.actbio.2005.04.004)
79. Soontornworajit, B., Zhou, J., Shaw, M. T., Fan, T. H. & Wang, Y. 2010 Hydrogel functionalization with DNA aptamers for sustained PDGF-BB release. Chem. Commun. 46, 1857-1859. (doi:10.1039/b924909e)
80. Willerth, S. M., Johnson, P. J., Maxwell, D. J., Parsons, S. R., Doukas, M. E. & Sakiyama-Elbert, S. E. 2007 Rationally designed peptides for controlled release of nerve growth factor from fibrin matrices. J. Biomed. Mater. Res. A 80, 13-23. (doi:10.1002/jbm.a.30844)
81. Hill, E., Boontheekul, T. & Mooney, D. J. 2006 Regulating activation of transplanted cells controls tissue regeneration. Proc. Natl Acad. Sci. USA 103, 2494-2499. (doi:10.1073/pnas.0506004103)
82. Silva, E. A., Kim, E. S., Kong, H. J. & Mooney, D. J. 2008 Material-based deployment enhances efficacy of endothelial progenitor cells. Proc. Natl Acad. Sci. USA 105, 14 347-14 352. (doi:10.1073/pnas.0803873105)
83. Lin, C. C., Metters, A. T. & Anseth, K. S. 2009 Functional PEG-peptide hydrogels to modulate local inflammation induced by the pro-inflammatory cytokine TNFalpha. Biomaterials 30, 4907-4914. (doi:10.1016/j.biomaterials.2009.05.083)
84. Davis, M. E., Hsieh, P. C., Takahashi, T., Song, Q., Zhang, S., Kamm, R. D., Grodzinsky, A. J., Anversa, P. & Lee, R. T. 2006 Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. Proc. Natl Acad. Sci. USA 103, 8155-8160. (doi:10.1073/pnas.0602877103)
85. Ito, Y. 2008 Covalently immobilized biosignal molecule materials for tissue engineering. Soft Matter 4, 46-56. (doi:10.1039/b708359a)
86. Kuhl, P. R. & Griffithcima, L. G. 1996 Tethered epidermal growth factor as a paradigm for growth factor-induced stimulation from the solid phase. Nat. Med. 2, 1022-1027. (doi:10.1038/nm0996-1022)
87. Mann, B. K., Schmedlen, R. H. & West, J. L. 2001 Tethered-TGF-beta increases extracellular matrix production of vascular smooth muscle cells. Biomaterials 22, 439-444. (doi:10.1016/S0142-9612(00)00196-4)
88. Harris, L. D., Kim, B. S. & Mooney, D. J. 1998 Open pore biodegradable matrices formed with gas foaming. J. Biomed. Mater. Res. 42, 396-402. (doi:10.1002/(SICI)1097-4636(19981205)42:3〈396::AID-JBM7〉3.0. CO;2-E)
89. Mooney, D. J., Baldwin, D. F., Suh, N. P., Vacanti, J. P. & Langer, R. 1996 Novel approach to fabricate porous sponges of poly(D,L-lactic-co- glycolic acid) without the use of organic solvents. Biomaterials 17, 1417-1422. (doi:10.1016/0142-9612(96)87284-X)
90. Sheridan, M. H., Shea, L. D., Peters, M. C. & Mooney, D. J. 2000 Bioabsorbable polymer scaffolds for tissue engineering capable of sustained growth factor delivery. J. Control. Release 64, 91-102. (doi:10.1016/S0168- 3659(99)00138-8)
91. Chen, R. R. & Mooney, D. J. 2003 Polymeric growth factor delivery strategies for tissue engineering. Pharm. Res. 20, 1103-1112. (doi:10.1023/A:1025034925152)
92. Desai, M. P., Labhasetwar, V., Walter, E., Levy, R. J. & Amidon, G. L. 1997 The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm. Res. 14, 1568-1573. (doi:10.1023/A:1012126301290)
93. Panyam, J. & Labhasetwar, V. 2003 Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 55, 329-347. (doi:10.1016/S0169-409X(02)00228-4)
94. Chen, F. M., Chen, R., Wang, X. J., Sun, H. H. & Wu, Z. F. 2009 In vitro cellular responses to scaffolds containing two microencapulated growth factors. Biomaterials 30, 5215-5224. (doi:10.1016/j.biomaterials.2009.06.009)
95. Hubbell, J. A. 1999 Bioactive biomaterials. Curr. Opin. Biotechnol. 10, 123-129. (doi:10.1016/S0958-1669(99)80021-4)
96. Meinel, L. et al. 2003 Localized insulin-like growth factor I delivery to enhance new bone formation. Bone 33, 660-672. (doi:10.1016/S8756-3282(03)00207- 2)
97. Shin, H., Jo, S. & Mikos, A. G. 2003 Biomimetic materials for tissue engineering. Biomaterials 24, 4353-4364. (doi:10.1016/S0142-9612(03)00339-9)
98. Siccardi, F. J. 1975 Considerations concerning the host-parasite relationship of Escherichia coli in poultry. Am. J. Vet. Res. 36, 572.
99. Wenk, E., Meinel, A. J., Wildy, S., Merkle, H. P. & Meinel, L. 2009 Microporous silk fibroin scaffolds embedding PLGA microparticles for controlled growth factor delivery in tissue engineering. Biomaterials 30, 2571-2581. (doi:10.1016/j.biomaterials.2008.12.073)
100. Meinel, L., Illi, O. E., Zapf, J., Malfanti, M., Peter Merkle, H. & Gander, B. 2001 Stabilizing insulin-like growth factor-I in poly(D,L-lactide-co- glycolide) microspheres. J. Control. Release 70, 193-202. (doi:10.1016/S0168- 3659(00)00352-7)
101. Rocha, F. G., Sundback, C. A., Krebs, N. J., Leach, J. K., Mooney, D. J., Ashley, S. W., Vacanti, J. P. & Whang, E. E. 2008 The effect of sustained delivery of vascular endothelial growth factor on angiogenesis in tissue-engineered intestine. Biomaterials 29, 2884-2890. (doi:10.1016/j. biomaterials.2008.03.026)
102. Zhu, X. H., Wang, C. H. & Tong, Y. W. 2009 In vitro characterization of hepatocyte growth factor release from PHBV/PLGA microsphere scaffold. J. Biomed. Mater. Res. A 89, 411-423. (doi:10.1002/jbm.a.31978)
103. Jain, R. A. 2000 The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 21, 2475-2490. (doi:10.1016/S0142-9612(00)00115-0)
104. Johnson, M. R., Lee, H. J., Bellamkonda, R. V. & Guldberg, R. E. 2009 Sustained release of BMP-2 in a lipid-based microtube vehicle. Acta Biomater. 5, 23-28. (doi:10.1016/j.actbio.2008.09.001)
105. Scott, R. C., Rosano, J. M., Ivanov, Z.,Wang, B., Chong, P. L., Issekutz, A. C., Crabbe, D. L. & Kiani, M. F. 2009 Targeting VEGF-encapsulated immunoliposomes to MI heart improves vascularity and cardiac function. FASEB J. 23, 3361-3367. (doi:10.1096/fj.08-127373)
106. Shive, M. S. & Anderson, J. M. 1997 Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev. 28, 5-24.
107. Chen, R. R., Silva, E. A., Yuen, W. W. & Mooney, D. J. 2007 Spatio-temporal VEGF and PDGF delivery patterns blood vessel formation and maturation. Pharm. Res. 24, 258-264. (doi:10.1007/s11095-006-9173-4)
108. Pepper, M. S., Ferrara, N., Orci, L. & Montesano, R. 1992 Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem. Biophys. Res. Commun. 189, 824-831. (doi:10.1016/0006-291X(92)92277-5)
109. Burdick, J. A., Ward, M., Liang, E., Young, M. J. & Langer, R. 2006 Stimulation of neurite outgrowth by neurotrophins delivered from degradable hydrogels. Biomaterials 27, 452-459. (doi:10.1016/j.biomaterials.2005.06.034) (Pubitemid 41457248)
110. Discher, D. E., Mooney, D. J. & Zandstra, P. W. 2009 Growth factors, matrices, and forces combine and control stem cells. Science 324, 1673-1677. (doi:10.1126/science.1171643)
111. Ali, O. A., Huebsch, N., Cao, L., Dranoff, G. & Mooney, D. J. 2009 Infection-mimicking materials to program dendritic cells in situ. Nat. Mater. 8, 151-158. (doi:10.1038/nmat2357)
112. Boontheekul, T. & Mooney, D. J. 2003 Protein-based signaling systems in tissue engineering. Curr. Opin. Biotechnol. 14, 559-565. (doi:10.1016/j. copbio.2003.08.004)
113. Santo, V. E., Frias, A. M., Carida, M., Cancedda, R., Gomes, M. E., Mano, J. F. & Reis, R. L. 2009 Carrageenan-based hydrogels for the controlled delivery of PDGF-BB in bone tissue engineering applications. Biomacromolecules 10, 1392-1401. (doi:10.1021/bm8014973)
114. Lee, K. Y. & Mooney, D. J. 2001 Hydrogels for tissue engineering. Chem. Rev. 101, 1869-1879. (doi:10.1021/cr000108x)
115. Zisch, A. H. et al. 2003 Cell-demanded release of VEGF from synthetic, biointeractive cell ingrowth matrices for vascularized tissue growth. FASEB J. 17, 2260-2262.
116. Holland, T. A., Tabata, Y. & Mikos, A. G. 2005 Dual growth factor delivery from degradable oligo (poly(ethylene glycol) fumarate) hydrogel scaffolds for cartilage tissue engineering. J. Control. Release 101, 111-125. (doi:10.1016/j.jconrel.2004.07.004)
117. Tabata, Y., Ikada, Y., Morimoto, K., Katsumata, H., Yabuta, T., Iwanaga, K. & Kakemi, M. 1999 Surfactant-free preparation of biodegradable hydrogel microspheres for protein release. J. Bioactive Compatible Polym. 14, 371-384.
118. Mikos, A. G., Lyman, M. D., Freed, L. E. & Langer, R. 1994 Wetting of poly(L-lactic acid) and poly(DL-lacticco-glycolic acid) foams for tissue culture. Biomaterials 15, 55-58. (doi:10.1016/0142-9612(94)90197-X)
119. Fournier, E., Passirani, C., Montero-Menei, C. N. & Benoit, J. P. 2003 Biocompatibility of implantable synthetic polymeric drug carriers: focus on brain biocompatibility. Biomaterials 24, 3311-3331. (doi:10.1016/S0142-9612(03) 00161-3)
120. Bouhadir, K. H., Lee, K. Y., Alsberg, E., Damm, K. L., Anderson, K. W. & Mooney, D. J. 2001 Degradation of partially oxidized alginate and its potential application for tissue engineering. Biotechnol. Prog. 17, 945-950. (doi:10.1021/bp010070p)
121. Boontheekul, T., Kong, H. J. & Mooney, D. J. 2005 Controlling alginate gel degradation utilizing partial oxidation and bimodal molecular weight distribution. Biomaterials 26, 2455-2465. (doi:10.1016/j.biomaterials. 2004.06.044)
122. De Souza, R., Zahedi, P., Allen, C. J. & Piquette-Miller, M. 2009 Biocompatibility of injectable chitosan-phospholipid implant systems. Biomaterials 30, 3818-3824. (doi:10.1016/j.biomaterials.2009.04.003)
123. Gupta, D., Tator, C. H. & Shoichet, M. S. 2006 Fast-gelling injectable blend of hyaluronan and methylcellulose for intrathecal, localized delivery to the injured spinal cord. Biomaterials 27, 2370-2379. (doi:10.1016/j.biomaterials.2005.11.015)
124. Jimenez Hamann, M. C., Tator, C. H. & Shoichet, M. S. 2005 Injectable intrathecal delivery system for localized administration of EGF and FGF-2 to the injured rat spinal cord. Exp. Neurol. 194, 106-119.
125. Jimenez Hamann, M. C., Tsai, E. C., Tator, C. H. & Shoichet, M. S. 2003 Novel intrathecal delivery system for treatment of spinal cord injury. Exp. Neurol. 182, 300-309. (doi:10.1016/S0014-4886(03)00040-2)
126. Kang, C. E., Poon, P. C., Tator, C. H. & Shoichet, M. S. 2009 A new paradigm for local and sustained release of therapeutic molecules to the injured spinal cord for neuroprotection and tissue repair. Tissue Eng. Part A 15, 595-604. (doi:10.1089/ten.tea.2007.0349)
127. Kapur, T. A. & Shoichet, M. S. 2004 Immobilized concentration gradients of nerve growth factor guide neurite outgrowth. J. Biomed. Mater. Res. A 68, 235-243.
128. Akiyoshi, K., Deguchi, S., Moriguchi, N., Yamaguchi, S. & Sunamoto, J. 1993 Self-aggregates of hydrophobized polysaccharides in water. Formation and characteristics of nanoparticles. Macromolecules 26, 3062-3068. (doi:10.1021/ma00064a011)
129. Kageyama, S. et al. 2008 Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogel. Cancer Sci. 99, 601-607. (doi:10.1111/j.1349-7006.2007.00705.x)
130. Kato, N., Hasegawa, U., Morimoto, N., Saita, Y., Nakashima, K., Ezura, Y., Kurosawa, H., Akiyoshi, K. & Noda, M. 2007 Nanogel-based delivery system enhances PGE2 effects on bone formation. J. Cell. Biochem. 101, 1063-1070. (doi:10.1002/jcb.21160)
131. Morimoto, N., Endo, T., Iwasaki, Y. & Akiyoshi, K. 2005 Design of hybrid hydrogels with self-assembled nanogels as cross-linkers: interaction with proteins and chaperone-like activity. Biomacromolecules 6, 1829-1834. (doi:10.1021/bm050156x)
132. Nomura, Y., Sasaki, Y., Takagi, M., Narita, T., Aoyama, Y. & Akiyoshi, K. 2005 Thermoresponsive controlled association of protein with a dynamic nanogel of hydrophobized polysaccharide and cyclodextrin: heat shock protein-like activity of artificial molecular chaperone. Biomacromolecules 6, 447-452. (doi:10.1021/bm049501t) (Pubitemid 40277045)
133. Silva, E. A. & Mooney, D. J. 2004 Synthetic extracellular matrices for tissue engineering and regeneration. Curr. Top. Dev. Biol. 64, 181-205. (doi:10.1016/S0070-2153(04)64008-7)
134. Ulijn, R. V., Bibi, N., Jayawarna, V., Thornton, P. D., Todd, S. J., Mart, R. J., Smith, A. M. & Gough, J. E. 2007 Bioresponsive hydrogels. Mater. Today 10, 40-48. (doi:10.1016/S1369-7021(07)70049-4)
135. Casanovas, J., Zanuy, D. & Aleman, C. 2006 Conducting polymer actuator mechanism based on the conformational flexibility of calix[4]arene. Angew. Chem. Int. Ed. Engl. 45, 1103-1105. (doi:10.1002/anie.200503304)
136. Domb, A. J., Turovsky, L. & Nudelman, R. 1994 Chemical interactions between drugs containing reactive amines with hydrolyzable insoluble biopolymers in aqueous solutions. Pharm. Res. 11, 865-868. (doi:10.1023/A:1018985909777)
137. Fu, K., Pack, D. W., Klibanov, A. M. & Langer, R. 2000 Visual evidence of acidic environment within degrading poly(lactic-co-glycolic acid) (PLGA) microspheres. Pharm. Res. 17, 100-106. (doi:10.1023/A:1007582911958)
138. Middaugh, C. R., Evans, R. K., Montgomery, D. L. & Casimiro, D. R. 1998 Analysis of plasmid DNA from a pharmaceutical perspective. J. Pharm. Sci. 87, 130-146. (doi:10.1021/js970367a)
139. Shim, W. S., Kim, S. W. & Lee, D. S. 2006 Sulfonamide-based pH- and temperature-sensitive biodegradable block copolymer hydrogels. Biomacromolecules 7, 1935-1941. (doi:10.1021/bm0600567)
140. Kim, H. K., Shim, W. S., Kim, S. E., Lee, K. H., Kang, E., Kim, J. H., Kim, K., Kwon, I. C. & Lee, D. S. 2009 Injectable in situ-forming pH/thermo-sensitive hydrogel for bone tissue engineering. Tissue Eng. Part A 15, 923-933. (doi:10.1089/ten.tea.2007.0407)
141. Shim, W. S., Yoo, J. S., Bae, Y. H. & Lee, D. S. 2005 Novel injectable pH and temperature sensitive block copolymer hydrogel. Biomacromolecules 6, 2930-2934. (doi:10.1021/bm050521k)
142. Gong, C. Y. et al. 2009 Biodegradable thermosensitive injectable PEG-PCL-PEG hydrogel for bFGF antigen delivery to improve humoral immunity. Growth Factors 27, 377-383. (doi:10.3109/08977190903159938)
143. Jeong, B., Lee, K. M., Gutowska, A. & An, Y. H. 2002 Thermogelling biodegradable copolymer aqueous solutions for injectable protein delivery and tissue engineering. Biomacromolecules 3, 865-868. (doi:10.1021/bm025536m)
144. Lee, E. S., Na, K. & Bae, Y. H. 2003 Polymeric micelle for tumor pH and folate-mediated targeting. J. Control. Release 91, 103-113. (doi:10.1016/S0168-3659(03)00239-6)
145. Lee, E. S., Na, K. & Bae, Y. H. 2005 Super pH-sensitive multifunctional polymeric micelle. Nano. Lett. 5, 325-329. (doi:10.1021/ nl0479987)
146. Putnam, D. 2006 Polymers for gene delivery across length scales. Nat. Mater. 5, 439-451. (doi:10.1038/nmat1645)
147. Matsusaki, M. & Akashi, M. 2005 Novel functional biodegradable polymer IV: pH-sensitive controlled release of fibroblast growth factor-2 from a poly (gamma-glutamic acid)-sulfonate matrix for tissue engineering. Biomacromolecules 6, 3351-3356. (doi:10.1021/bm050369m)
148. Huynh, D. P., Nguyen, M. K., Pi, B. S., Kim, M. S., Chae, S. Y., Lee, K. C., Kim, B. S., Kim, S. W. & Lee, D. S. 2008 Functionalized injectable hydrogels for controlled insulin delivery. Biomaterials 29, 2527-2534. (doi:10.1016/j.biomaterials.2008.02.016)
149. Little, S. R., Lynn, D. M., Ge, Q., Anderson, D. G., Puram, S. V., Chen, J., Eisen, H. N. & Langer, R. 2004 Poly-beta amino ester-containing microparticles enhance the activity of nonviral genetic vaccines. Proc. Natl Acad. Sci. USA 101, 9534-9539. (doi:10.1073/pnas.0403549101)
150. Lynn, D. M. & Langer, R. 2000 Degradable poly(beta-amino esters): synthesis, characterization, and self-assembly with plasmid DNA. J. Am. Chem. Soc. 122, 10 761-10 768. (doi:10.1021/ja0015388)
151. Wu, D. Q., Sun, Y. X., Xu, X. D., Cheng, S. X., Zhang, X. Z. & Zhuo, R. X. 2008 Biodegradable and pH-sensitive hydrogels for cell encapsulation and controlled drug release. Biomacromolecules 9, 1155-1162. (doi:10.1021/bm7010328)
152. Simoes, S., Moreira, J. N., Fonseca, C., Duzgunes, N. & De Lima, M. C. 2004 On the formulation of pH-sensitive liposomes with long circulation times. Adv. Drug Deliv. Rev. 56, 947-965. (doi:10.1016/j.addr.2003.10.038)
153. Murthy, N., Xu,M., Schuck, S., Kunisawa, J., Shastri, N. & Frechet, J. M. 2003 A macromolecular delivery vehicle for protein-based vaccines: acid-degradable protein-loaded microgels. Proc. Natl Acad. Sci. USA 100, 4995-5000. (doi:10.1073/pnas.0930644100)
154. Casadei,M. A., Pitarresi, G., Calabrese, R., Paolicelli, P. & Giammona, G. 2008 Biodegradable and pH-sensitive hydrogels for potential colon-specific drug delivery: characterization and in vitro release studies. Biomacromolecules 9, 43-49. (doi:10.1021/bm700716c)
155. Klouda, L. & Mikos, A. G. 2008 Thermoresponsive hydrogels in biomedical applications. Eur. J. Pharm. Biopharm. 68, 34-45. (doi:10.1016/j.ejpb.2007.02.025)
156. Hacker, M. C., Klouda, L., Ma, B. B., Kretlow, J. D. & Mikos, A. G. 2008 Synthesis and characterization of injectable, thermally and chemically gelable, amphiphilic poly(N-isopropylacrylamide)-based macromers. Biomacromolecules 9, 1558-1570. (doi:10.1021/bm8000414)
157. Reddy, T. T., Kano, A., Maruyama, A., Hadano, M. & Takahara, A. 2008 Thermosensitive transparent semi-interpenetrating polymer networks for wound dressing and cell adhesion control. Biomacromolecules 9, 1313-1321. (doi:10.1021/bm701390f)
158. Fundueanu, G., Constantin, M. & Ascenzi, P. 2008 Preparation and characterization of pH- and temperature-sensitive pullulan microspheres for controlled release of drugs. Biomaterials 29, 2767-2775. (doi:10.1016/j. biomaterials.2008.03.025)
159. Stover, T. C., Kim, Y. S., Lowe, T. L. & Kester, M. 2008 Thermoresponsive and biodegradable linear-dendritic nanoparticles for targeted and sustained release of a pro-apoptotic drug. Biomaterials 29, 359-369. (doi:10.1016/j.biomaterials.2007.09.037)
160. Saim, A. B., Cao, Y., Weng, Y., Chang, C. N., Vacanti, M. A., Vacanti, C. A. & Eavey, R. D. 2000 Engineering autogenous cartilage in the shape of a helix using an injectable hydrogel scaffold. Laryngoscope 110, 1694-1697. (doi:10.1097/00005537-200010000-00023)
161. Fisher, J. P., Jo, S., Mikos, A. G. & Reddi, A. H. 2004 Thermoreversible hydrogel scaffolds for articular cartilage engineering. J. Biomed. Mater. Res. A 71, 268-274.
162. Seong, J. Y., Jun, Y. J., Jeong, B. & Sohn, Y. S. 2005 New thermogelling poly (organophosphazenes) with methoxypoly(ethylene glycol) and oligopeptide as side groups. Polymer 46, 5075-5081. (doi:10.1016/j.polymer.2005. 04.024)
163. Lutolf, M. P., Weber, F. E., Schmoekel, H. G., Schense, J. C., Kohler, T., Muller, R. & Hubbell, J. A. 2003 Repair of bone defects using synthetic mimetics of collagenous extracellular matrices. Nat. Biotechnol. 21, 513-518. (doi:10.1038/nbt818)
164. Bremer, C., Tung, C. H. & Weissleder, R. 2001 In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat. Med. 7, 743-748. (doi:10.1038/89126)
165. Harris, T. J., Von Maltzahn, G., Lord, M. E., Park, J. H., Agrawal, A., Min, D. H., Sailor, M. J. & Bhatia, S. N. 2008 Protease-triggered unveiling of bioactive nanoparticles. Small 4, 1307-1312. (doi:10.1002/smll.200701319)
166. Thornton, P. D., Mcconnell, G. & Ulijn, R. V. 2005 Enzyme responsive polymer hydrogel beads. Chem. Commun. 5913-5915. (doi:10.1039/b511005j)
167. Um, S. H., Lee, J. B., Park, N., Kwon, S. Y., Umbach, C. C. & Luo, D. 2006 Enzyme-catalysed assembly of DNA hydrogel. Nat. Mater. 5, 797-801. (doi:10.1038/nmat1741)
168. Murakami, Y. & Maeda, M. 2005 DNA-responsive hydrogels that can shrink or swell. Biomacromolecules 6, 2927-2929. (doi:10.1021/bm0504330)
169. Miyata, T., Asami, N. & Uragami, T. 1999 A reversibly antigen-responsive hydrogel. Nature 399, 766-769. (doi:10.1038/21619)
170. Ehrbar, M., Schoenmakers, R., Christen, E. H., Fussenegger, M. & Weber, W. 2008 Drug-sensing hydrogels for the inducible release of biopharmaceuticals. Nat. Mater. 7, 800-804. (doi:10.1038/nmat2250)
171. Ehrick, J. D., Deo, S. K., Browning, T.W., Bachas, L. G., Madou, M. J. & Daunert, S. 2005 Genetically engineered protein in hydrogels tailors stimuli-responsive characteristics. Nat. Mater. 4, 298-302. (doi:10.1038/ nmat1352)
172. Kobatake, S., Takami, S., Muto, H., Ishikawa, T. & Irie, M. 2007 Rapid and reversible shape changes of molecular crystals on photoirradiation. Nature 446, 778-781. (doi:10.1038/nature05669)
173. Lendlein, A., Jiang, H., Junger, O. & Langer, R. 2005 Light-induced shape-memory polymers. Nature 434, 879-882. (doi:10.1038/nature03496)
174. Sumaru, K., Kameda, M., Kanamori, T. & Shinbo, T. 2004 Reversible and efficient proton dissociation of spirobenzopyran-functionalized poly(N-isopropylacrylamide) in aqueous solution triggered by light irradiation and temporary temperature rise. Macromolecules 37, 7854-7856. (doi:10.1021/ma0487249)
175. Jager, E. W., Smela, E. & Inganas, O. 2000 Microfabricating conjugated polymer actuators. Science 290, 1540-1545. (doi:10.1126/science.290. 5496.1540)
176. Welch, P. M. 2005 A tunable dendritic molecular actuator. Nano Lett. 5, 1279-1283. (doi:10.1021/nl050422c)
177. Yun, Y., Shanov, V., Tu, Y., Schulz, M. J., Yarmolenko, S., Neralla, S., Sankar, J. & Subramaniam, S. 2006 A multi-wall carbon nanotube tower electrochemical actuator. Nano Lett. 6, 689-693. (doi:10.1021/nl052435w)
178. Hu, S. H., Liu, T. Y., Huang, H. Y., Liu, D. M. & Chen, S. Y. 2008 Magnetic-sensitive silica nanospheres for controlled drug release. Langmuir 24, 239-244. (doi:10.1021/la701570z)
179. Kloxin, A. M., Kasko, A. M., Salinas, C. N. & Anseth, K. S. 2009 Photodegradable hydrogels for dynamic tuning of physical and chemical properties. Science 324, 59-63. (doi:10.1126/science.1169494)
180. Lee, K. Y., Peters, M. C., Anderson, K. W. & Mooney, D. J. 2000 Controlled growth factor release from synthetic extracellular matrices. Nature 408, 998-1000. (doi:10.1038/35044106)
181. Laham, R. J., Sellke, F.W., Edelman, E. R., Pearlman, J. D., Ware, J. A., Brown, D. L., Gold, J. P. & Simons, M. 1999 Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. Circulation 100, 1865-1871.
182. Ruel, M., Laham, R. J., Parker, J. A., Post, M. J., Ware, J. A., Simons, M. & Sellke, F. W. 2002 Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J. Thorac. Cardiovasc. Surg. 124, 28-34. (doi:10.1067/mtc.2002.121974)
183. Govender, S. et al. 2002 Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J. Bone Joint Surg. Am. 84-A, 2123-2134.
184. Jones, A. L., Bucholz, R. W., Bosse, M. J., Mirza, S. K., Lyon, T. R., Webb, L. X., Pollak, A. N., Golden, J. D. & Valentin-Opran, A. 2006 Recombinant human BMP-2 and allograft compared with autogenous bone graft for reconstruction of diaphyseal tibial fractures with cortical defects. A randomized, controlled trial. J. Bone Joint Surg. Am. 88, 1431-1441. (doi:10.2106/JBJS.E.00381)
185. Vaccaro, A. R., Lawrence, J. P., Patel, T., Katz, L. D., Anderson, D. G., Fischgrund, J. S., Krop, J., Fehlings, M. G. & Wong, D. 2008 The safety and efficacy of OP-1 (rhBMP-7) as a replacement for iliac crest autograft in posterolateral lumbar arthrodesis: a long-term (>4 years) pivotal study. Spine 33, 2850-2862. (doi:10.1097/BRS.0b013e31818a314d)
186. Vaccaro, A. R. et al. 2008 The safety and efficacy of OP-1 (rhBMP-7) as a replacement for iliac crest autograft for posterolateral lumbar arthrodesis: minimum 4-year follow-up of a pilot study. Spine J. 8, 457-465. (doi:10.1016/j.spinee.2007.03.012)
187. Mooney, D. J., Kaufmann, P. M., Sano, K., Mcnamara, K. M., Vacanti, J. P. & Langer, R. 1994 Transplantation of hepatocytes using porous, biodegradable sponges. Transplant Proc. 26, 3425-3426.
188. Hsu, Y. Y., Gresser, J. D., Trantolo, D. J., Lyons, C. M., Gangadharam, P. R. & Wise, D. L. 1997 Effect of polymer foam morphology and density on kinetics of in vitro controlled release of isoniazid from compressed foam matrices. J. Biomed. Mater. Res. 35, 107-116. (doi:10.1002/(SICI)1097- 4636(199704)35:1〈107::AID-JBM11〉3.0.CO;2-G)
189. Whang, K., Thomas, C. H., Healy, K. E. & Nuber, G. 1995 A novel method to fabricate bioabsorbable scaffolds. Polymer 36, 837-842. (doi:10.1016/0032-3861(95)93115-3)
190. Hua, F. J., Kim, G. E., Lee, J. D., Son, Y. K. & Lee, D. S. 2002 Macroporous poly(L-lactide) scaffold. 1. Preparation of a macroporous scaffold by liquid-liquid phase separation of a PLLA-dioxane-water system. J. Biomed. Mater. Res. 63, 161-167. (doi:10.1002/jbm.10121)
191. Lo, H., Ponticiello, M. S. & Leong, K.W. 1995 Fabrication of controlled release biodegradable foams by phase separation. Tissue Eng. 1, 15-28. (doi:10.1089/ten.1995.1.15)
192. Thomson, R. C., Yaszemski, M. J., Powers, J. M. & Mikos, A. G. 1995 Fabrication of biodegradable polymer scaffolds to engineer trabecular bone. J. Biomater. Sci. Polym. Ed. 7, 23-38. (doi:10.1163/156856295X00805)
193. Busby, W., Cameron, N. R. & Jahoda, C. A. 2001 Emulsion-derived foams (PolyHIPEs) containing poly(epsilon-caprolactone) as matrixes for tissue engineering. Biomacromolecules 2, 154-164. (doi:10.1021/bm0000889)
194. Bryant, S. J. & Anseth, K. S. 2001 The effects of scaffold thickness on tissue engineered cartilage in photocrosslinked poly(ethylene oxide) hydrogels. Biomaterials 22, 619-626. (doi:10.1016/S0142-9612(00)00225-8)
195. Temenoff, J. S., Park, H., Jabbari, E., Conway, D. E., Sheffield, T. L., Ambrose, C. G. & Mikos, A. G. 2004 Thermally cross-linked oligo(poly(ethylene glycol) fumarate) hydrogels support osteogenic differentiation of encapsulated marrow stromal cells in vitro. Biomacromolecules 5, 5-10. (doi:10.1021/bm030067p)